In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gene therapy start-up Homology Medicines raises $43.5mm in Series A capital

Executive Summary

Homology Medicines Inc. (gene therapy for rare diseases) raised $43.5mm in its Series A financing round. The preferred stock financing was led by 5AM Ventures and ARCH Venture Partners with participation from Temasek, Deerfield Management, and ARCH Overage Fund. The company also appointed its leadership and advisory board.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies